A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?

Prostate

Volumn 75, Issue 11, 2015, Pages 1177-1186

  Gontero, Paolo ^a   Marra, Giancarlo ^a   Soria, Francesco ^a   Oderda, Marco ^a   Zitella, Andrea ^a   Baratta, Francesca ^a   Chiorino, Giovanna ^b   Gregnanin, Ilaria ^b   Daniele, Lorenzo ^a   Cattel, Luigi ^a   Frea, Bruno ^a   Brusa, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Laboratory of Cancer Genomics   (Italy)

Author keywords

ASAP; chemoprevention; HGPIN; miRNA; prostate cancer; randomized controlled trial

Indexed keywords

ANTIOXIDANT; GREEN TEA EXTRACT PLUS LYCOPENE PLUS SELENOMETHIONINE; MESSENGER RNA; MICRORNA 125B 5P; MICRORNA 92A 3P; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CAROTENOIDS; LYCOPENE; PROSTATE-SPECIFIC ANTIGEN; SELENIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATYPICAL SMALL ACINAR PROLIFERATION; CANCER PREVENTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; EORTC QLQ PR25 QUESTIONNAIRE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIFOCAL HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRECANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; ULTRAVIOLET SPECTROPHOTOMETRY; BIOLOGICAL AVAILABILITY; BIOPSY; BLOOD; CHEMOPREVENTION; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; HUMANS; METABOLISM; METHODS; PATHOLOGY; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; BIOPSY; CAROTENOIDS; CHEMOPREVENTION; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SELENIUM; TREATMENT OUTCOME;

EID: 84932197198     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22999     Document Type: Article

References (35)

1. Van Poppel H, Tombal B,. Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 2011; 3: 91-100.
2. Kheirandish P, Chinegwundoh F,. Ethnic differences in prostate cancer. Br J Cancer 2011; 105 (4): 481-485.
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H,. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977; 20 (5): 680-688.
4. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A,. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66 (2): 1234-1240.
5. Mohanty NK, Saxena S, Singh UP, Goyal NK, Arora RP,. Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia. Urol Oncol 2005; 23 (6): 383-385.
6. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, Group JS,. Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am J Epidemiol 2008; 167 (1): 71-77.
7. Joniau S, Goeman L, Roskams T, Lerut E, Oyen R, Van Poppel H,. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology 2007; 69 (6): 1102-1106.
8. Oderda M, Gontero P,. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: Is repeat biopsy still necessary? BJU Int 2009; 104 (11): 1554-1556.
9. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA,. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Nat Cancer Inst 2014; 106 (3): djt56.
10. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: A global perspective. Washington DC: AICR, 2007.
11. EMA scientific guideline on stability for human medicines. [www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000361.jsp&mid=WC0b01ac0580028eb1].
12. Talwar D, Ha TK, Cooney J, Brownlee C, O'Reilly DS,. A routine method for the simultaneous measurement of retinol, alpha-tocopherol and five carotenoids in human plasma by reverse phase HPLC. Clin. Chim Acta 1998; 270 (2): 85-100.
13. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, Camara-Lopes LH, Srougi M,. MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 2013; 31 (6): 796-801.
14. Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, Li X, Wang J, Zeng H,. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate 2014; 74 (7): 756-767.
15. Etminan M, FitzGerald JM, Gleave M, Chambers K,. Intake of selenium in the prevention of prostate cancer: A systematic review and meta-analysis. Cancer Causes Control 2005; 16 (9): 1125-1131.
16. Lin YW, Hu ZH, Wang X, Mao QQ, Qin J, Zheng XY, Xie LP,. Tea consumption and prostate cancer: An updated meta-analysis. World J Surg Oncol 2014; 12: 38.
17. Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM Jr,. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res 2011; 4 (11): 1761-1769.
18. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK,. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 2008; 138 (1): 49-53.
19. Vencio EF, Pascal LE, Page LS, Denyer G, Wang AJ, Ruohola-Baker H, Zhang S, Wang K, Galas DJ, Liu AY,. Embryonal carcinoma cell induction of miRNA and mRNA changes in co-cultured prostate stromal fibromuscular cells. J Cell Physiol 2011; 226 (6): 1479-1488.
20. Walter BA, Valera VA, Pinto PA, Merino MJ,. Comprehensive microRNA profiling of prostate cancer. J Cancer 2013; 4 (5): 350-357.
21. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM,. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68 (15): 6162-6170.
22. Brausi M, Rizzi F, Bettuzzi S,. Chemoprevention of human prostate cancer by green tea catechins: Two years later A follow-up update. Eur Urol 2008; 54 (2): 472-473.
23. Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff V, Willett WC, Giovannucci E,. Plasma and dietary carotenoids, and the risk of prostate cancer: A nested case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13 (2): 260-269.
24. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr,. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 2009; 301 (1): 39-51.
25. Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR,. Progression from high-grade prostatic intraepithelial neoplasia to cancer: A randomized trial of combination vitamin-E, soy, and selenium. J Clin Oncol 2011; 29 (17): 2386-2390.
26. Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB,. Serum lycopene, other carotenoids, and prostate cancer risk: A nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007; 16 (5): 962-968.
27. Kristal AR, Arnold KB, Neuhouser ML, Goodman P, Platz EA, Albanes D, Thompson IM,. Diet, supplement use, and prostate cancer risk: Results from the prostate cancer prevention trial. Am J Epidemiol 2010; 172 (5): 566-577.
28. Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C, Hong GM, Borro M, Simmaco M,. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci 2014; 15 (1): 1433-1440.
29. Chen J, Song Y, Zhang L,. Effect of lycopene supplementation on oxidative stress: An exploratory systematic review and meta-analysis of randomized controlled trials. J Med Food 2013; 16 (5): 361-374.
30. Martinez EE, Darke AK, Tangen CM, Goodman PJ, Fowke JH, Klein EA, Abdulkadir SA,. A functional variant in N KX3. 1 associated with prostate cancer risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res 2014; 7 (9): 950-957.
31. Chhabra R, Dubey R, Saini N,. Cooperative and individualistic functions of the microRNAs in the miR-23a∼27a∼24-2 cluster and its implication in human diseases. Mol Cancer 2010; 9: 232.
32. Tian L, Fang YX, Xue JL, Chen JZ,. Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PloS ONE 2013; 8 (9): e75885.
33. Velicer CM, Ulrich CM,. Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J Clin Oncol 2008; 26 (4): 665-673.
34. Martinez EE, Anderson PD, Logan M, Abdulkadir SA,. Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice. PloS ONE 2012; 7 (10): e46792.
35. Boon H, Westlake K, Stewart M, Gray R, Fleshner N, Gavin A, Brown JB, Goel V,. Use of complementary/alternative medicine by men diagnosed with prostate cancer: Prevalence and characteristics. Urology 2003; 62 (5): 849-853.